Andere talen GeoVax Labs, Inc.

Aandelen

GOVX

US3736786068

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 25-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,47 ^USD	-4,55%		-3,29%	-72,85%

28/03	GeoVax Labs, Inc. presenteert gegevens over GEO-CM04S1, een Covid-19 vaccin van de volgende generatie, op het World Vaccine Congress	CI
06/03	GeoVax Labs, Inc. Bereikt mijlpaal in overgang naar commercieel gevalideerd productiesysteem	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine	04/04
GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress	28/03
GeoVax Labs, Inc. to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress	28/03
GeoVax to Present at the 36th Annual Roth Conference	12/03
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System	06/03
GeoVax Labs, Inc. Achieves Milestone in Transition to Commercially Validated Manufacturing System	06/03
GeoVax Reports 2023 Year-End Financial Results and Provides Business Update	29/02
GeoVax Labs, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024	22/02
GeoVax to Present at the 2024 BIO CEO & Investor Conference	19/02
GeoVax Labs Gets Two Patents from US Patent and Trademark Office	13/02
GeoVax Announces Multiple Patent Issuances and Allowances	13/02
GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster	06/02
Geovax Reports Positive Interim Data from Phase 2 Clinical Trial of Geo-Cm04s1 as A Universal Covid-19 Vaccine Booster	06/02
GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement	29/01
GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology	08/01
Geovax Appoints Marc Pipas as Executive Medical Director, Oncology	08/01
GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients	04/01
GeoVax Labs, Inc. Announces Gedeptin Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients	04/01
GeoVax Announces Issuance of Malaria Vaccine Patent	03/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen GeoVax Labs, Inc.

Aandelen

GOVX

US3736786068

Andere talen

Filters